Scientists discovered a key transcription factor regulating T cell survival and immunological memory. Overexpressing this factor in CAR-T cells improved therapy efficiency for cancer treatments. Improved therapies could benefit patients with B cell lymphoma and other diseases.
Researchers at La Jolla Institute for Immunology report that protein TL1A drives fibrosis in several mouse models, triggering tissue remodeling and making it harder for lungs and airways to function normally. This discovery suggests potential targets for therapeutics aimed at reducing fibrosis and tissue remodeling.
The University of Louisville will establish a Center for Cancer Immunology and Immunotherapy to develop and improve cancer treatments that utilize the immune system. Researchers will focus on advancing strategies to use the immune response to fight cancer, with the goal of saving lives through immunotherapies.
Scientists at La Jolla Institute for Immunology discover that high-valency antigens can lead to a more-is-better immune system reaction, while low-valency antigens result in a smaller, more targeted B cell response. The study suggests that selecting antigens with the right valency will depend on the disease being targeted.
A new study from La Jolla Institute for Immunology found that blocking nerve signals to the pancreas could stop patients from ever developing type 1 diabetes. The researchers used a mouse model and discovered that blocking sympathetic nerve signals protected mice from beta cell death.
Scientists at La Jolla Institute for Immunology have tracked down the rare stem cells that generate neutrophils in human bone marrow, offering a potential path for intervening in diseases where neutrophil development goes awry. This research may also provide clues to COVID-19 and cancer drug targets.
A recent study published in Nature Communications reveals that an enzyme called HDAC3 plays a crucial role in regulating lung macrophage development and homeostasis. The research found that inhibiting this enzyme may provide a new therapeutic approach for treating lung cancer and inflammatory diseases in the airway.
The Michelson Prizes support the innovative work of Dr. Danika Hill and Dr. Michael Birnbaum on discovering targets for long-lived humoral immunity and identifying specific antigens in HIV vaccines.
A new study reveals that certain T lymphocytes can increase inflammation and worsen atherosclerosis cases, contrary to their usual role as immune system defenders. Researchers at La Jolla Institute for Immunology are working to design a safe anti-atherosclerosis vaccine by harnessing the power of T cells.
Researchers discovered a rare single gene mutation in a patient that eliminated an immune cell population, namely MAIT cells. The study demonstrates the impact of a single gene mutation on the human immune system and advances personalized medicine.
A new study from La Jolla Institute for Immunology reveals that a metabolic enzyme called ADA2 inhibits inflammation in blood vessels and restrains the immune system. The researchers found that ADA2's loss stimulates a robust innate immune response, which can lead to harmful inflammation.
Researchers at Tokyo University of Science discovered that transcription factor PU.1 plays a crucial role in regulating PD-L2 expression, which has implications for developing new treatments for immune-related disorders and cancer. The study sheds light on the molecular events underlying PD-L2 regulation.
Researchers discovered that a protein called Neuropilin-1 (NRP1) suppresses immune responses to cancer. Blocking NRP1 improves the immune system's ability to remember tumors, leading to better protection against recurrence and improved response to immunotherapy.
A multidisciplinary research team proposes integrating diverse species and environments into immunology research to develop treatments and vaccines for viruses. Observations in nature, such as the cowpox virus, have led to vaccine discoveries; now, studying new species can yield large payoffs.
A new study found that T cells targeting the SARS-CoV-2 virus can help fight COVID-19, even in severe cases. The research also reveals similar responses to the virus among Dutch and American patients.
Researchers at La Jolla Institute for Immunology have identified a key protein controlling T follicular helper cell (Tfh) differentiation. The protein Bcl6 acts as a master regulator in the immune system, blocking or promoting gene expression to control immune responses. This study opens the door to designing vaccines and therapies tha...
The University of Maryland School of Medicine will partner with the Defense Advanced Research Projects Agency to rapidly test hundreds of drugs approved for other conditions to see if they can be repurposed to prevent or treat COVID-19.
Researchers at Scripps Research Institute isolate powerful coronavirus-neutralizing antibodies from recovered COVID-19 patients and test their effectiveness in animals, achieving results in under seven weeks. The discovery offers hope for a rapid response to the pandemic and potential clinical trials for treatment and preventive measures.
Researchers at La Jolla Institute for Immunology have uncovered a previously unknown subset of T cells that may control allergic immune reactions and asthma. These cells, which express an 'interferon response signature,' may dampen the activation of helper T cells and reduce inflammation.
Researchers at La Jolla Institute for Immunology discovered that antibodies against one virus can make another more severe. However, a specific type of T cell can counteract this effect. The study suggests the need for future vaccines to elicit a balanced response from both antibodies and T cells.
A new study in Frontiers in Immunology found that treatment with interferon (IFN)-α2b significantly reduced the duration of detectable virus in upper respiratory tract and blood levels of inflammatory proteins IL-6 and CRP, suggesting potential for an effective antiviral intervention
Scientists have discovered a strong immune response to SARS-CoV-2 in people who have recovered from COVID-19, which provides a benchmark for testing vaccine candidates. The study also found substantial cross-reactivity against common cold coronaviruses, suggesting potential preexisting immunity.
A researcher at Penn State is testing the efficacy of common disinfectants against viruses. The study aims to determine the optimal contact time for sanitizing surfaces to reduce the spread of COVID-19.
A new type of vaccination has been shown to substantially enhance and sustain protection from HIV in monkeys, with a two-armed approach stimulating both serum and cellular immunity. The findings have broad implications for immunologists pursuing vaccines for other diseases, particularly those caused by coronaviruses.
Researchers have developed a method of lymphocytic vaccination to counter autoimmune diseases, proving clinically effective in treating multiple sclerosis and rheumatoid arthritis. The technology involves creating an immunology cell bank to enhance immunological protection against infection.
Researchers found a positive correlation between viral RNA load and organ damage in COVID-19 patients. Higher viral loads were associated with increased inflammatory factors and longer recovery times.
The American Gastroenterological Association (AGA) has released new guidelines for the management of eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus triggered by allergens. Topical steroids are recommended as a first-line treatment, while proton pump inhibition, diet therapy, and esophageal dilation are ...
The Coronavirus Immunotherapy Consortium will streamline and accelerate the development of antibody therapies against SARS-CoV-2, providing crucial insights to guide vaccine development. CoVIC brings together scientists worldwide to share and evaluate candidate antibodies in a blinded analysis.
A study published in The Journal of Allergy and Clinical Immunology: In Practice found that children with food protein-induced enterocolitis syndrome (FPIES) are at a higher risk of developing other allergic conditions. Despite this, the researchers did not find a direct causal link between FPIES and these other allergies.
Scientists at La Jolla Institute for Immunology found no evidence linking CD4 T cells to severe dengue hemorrhagic fever. Instead, they discovered a novel T cell response that may help counteract inflammation, suggesting a new direction for developing effective vaccines.
Researchers from the La Jolla Institute for Immunology identified a new role for HMCES in alternative end-joining, a secondary strategy used by mammalian cells to rejoin severe cuts across both strands of DNA. This discovery suggests that HMCES is versatile enough to accomplish entirely different tasks in response to DNA damage.
A new study shows an association between a family history of cancer and childhood asthma diagnosis in over 20% of children, highlighting the importance of extra asthma screening efforts.
In unvaccinated children, measles infection can cause a significant weakening of the immune system, leading to impaired immunity against viruses and bacteria for months or even years. This phenomenon, known as 'immune amnesia,' was observed in two separate studies published in Science Immunology and Science.
Researchers at TalTech have identified a new receptor, P2X4, in human eosinophils that plays a key role in the communication between the immune system and nervous system. The discovery has implications for understanding multiple sclerosis and cancerous lesions.
La Jolla Institute of Immunology and Seqster partner to accelerate discovery of personalized treatments for severe asthma through longitudinal data analysis. The collaboration enables 5000 participants to share medical records, genomic data, and wearable device data with researchers.
The NIH has awarded contracts to establish three new centers for immunology research to accelerate progress in TB vaccine development. The program aims to develop a comprehensive understanding of the immune responses required to prevent TB infection and disease.
Researchers at Scripps Research Institute have discovered a potential biological marker for early detection of type 1 diabetes using single-cell analysis of immune cells. The discovery could lead to earlier intervention and prevention of the disease, which affects over 1.25 million Americans.
Researchers at The Mount Sinai Hospital have identified a unique cell signature associated with drug resistance in Crohn's disease patients. This discovery may enable the development of personalized treatment plans and improved patient outcomes.
Researchers at La Jolla Institute for Immunology identified the molecular properties of antibodies that neutralize Lassa virus. By understanding these properties, they can create a map for rational vaccine design, aiming to develop effective treatments or vaccines against this deadly disease.
A new study created lab mice by implanting embryos from laboratory animals into wild mice, resulting in a model that accurately predicts human response to drugs. This novel approach has the potential to improve translational research value for immunology, potentially preventing failed clinical trials.
In a large 24-week study, rheumatoid arthritis patients saw substantial improvement from daily use of an experimental compound. Filgotinib, a selective JAK-1 inhibitor, showed significant benefits in reducing joint swelling and improving disease activity compared to placebo.
Researchers found signs of activation in resting B cells, which precede the activation of immune cells in people with systemic lupus erythematosus (SLE), a previously underappreciated stage of the disease. The study identified patterns of gene activity that could be used as biomarkers for disease development.
Three young scientists, Murad Mamedov, et al., receive $150,000 for their novel methods in understanding the human immune system. The Michelson Prizes recognize groundbreaking research using genomics, AI, and machine learning to transform human health.
A broadly effective dengue vaccine is still a substantial challenge due to the disease's complexity. However, experts suggest that rethinking existing concepts and developing live attenuated vaccines could lead to more effective solutions.
Scientists at La Jolla Institute for Immunology developed a new HIV vaccine delivery strategy that enhances the protective immune response by slowly releasing vaccine doses. This approach, called escalating dose strategy, leads to stronger and more neutralizing antibodies against the virus.
Researchers at the La Jolla Institute for Immunology discovered that genetic deletion of TET2 and TET3 in mouse B cells impairs the generation of functional IgG antibodies, highlighting the critical role of epigenetic control in healthy immune cell function.
The UMD Institute for Genome Sciences has been awarded $17.5 million to continue its genome-based investigation of polymicrobial infectious disease outcomes. The grant will support research into host-pathogen-microbiome interactions, focusing on multiple bacteria, fungal pathogens, and parasitic tropical diseases.
A new study by University of Pittsburgh researchers has identified a previously unknown mechanism used by tumors to suppress the immune system. The study found that tumors use two types of immune cells, regulatory T cells (Tregs), to release inhibitory cytokines, which activate a protein called BLIMP1 and disable killer T cells.
Researchers discovered a new mechanism by which influenza A viruses alter host immune systems, making them more susceptible to deadly bacterial infections. The PDZ-binding motif regulates cytokine production, controlling the severity of secondary bacterial infections.
A recent study by WVU researchers found that stroke patients' microbiomes may still be out of balance a month after the stroke has passed. The team discovered changes in the structure of their guts, including less prominent beneficial bacteria and increased inflammation.
A new study found that urban children with poorly controlled asthma experience higher school absences and lower academic performance. Ethnic minority children, particularly Latino kids, face greater disparities in academic outcomes due to unique stressors related to their background and migration experiences.
Researchers at the La Jolla Institute of Immunology have identified Nr4a transcription factors as a key regulator of T cell exhaustion in solid tumors. By deleting these proteins from CAR T cells, mice with tumors showed improved survival and tumor regression, offering new hope for effective cancer immunotherapies.
A study by La Jolla Institute for Immunology finds that recurrent group A strep tonsillitis is caused by a combination of genetic and immunological factors, including an insufficient antibody response against SpeA. This understanding may lead to the development of a vaccine to protect against strep throat.
This special issue of Viral Immunology delves into the intricacies of viral brain infection, focusing on immune responses such as IFNα/ß signaling and chemokine CXCL10. Research reveals the importance of astrocytes, brain-resident memory T-cells, and chemokines in protecting against encephalitic viruses.
The University of Colorado Anschutz Medical Campus will partner with the Allen Institute for Immunology to understand the human immune system and find novel mechanisms to halt or reverse rheumatoid arthritis. The research program aims to identify biomarkers for early detection and develop new treatments for this debilitating disease.
A recent study published in Nature Immunology reveals that lung-resident memory B cells can provide more effective immunity against influenza infections. These cells are able to respond quickly and produce antibodies after a second infection, suggesting they play a crucial role in respiratory virus immunity.
Researchers at Mainz University Medical Center discovered a new signal pathway employed by skin cancer cells to evade the immune system. The ICER protein plays a significant role in this process, leading to rapid tumor growth and inflammation.
The LEO Foundation Skin Immunology Research Center will bring together leading researchers to provide new knowledge for better diagnoses and treatments of psoriasis and eczema. The center aims to strengthen the immune system's fight against over 3,000 known skin diseases.
A medically challenging case presented at the American College of Allergy, Asthma and Immunology Annual Scientific Meeting found that allergy shots provided significant benefits to a patient with severe eczema. The treatment successfully reduced the need for high-dose steroid therapy and improved symptoms such as itching and dry skin.
A recent study published at the American College of Allergy, Asthma and Immunology Annual Scientific Meeting found that epinephrine auto injectors (EAIs) can still function properly even if they are unintentionally frozen. Researchers tested 104 devices and found no significant difference in weight changes before and after freezing.